- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00422903
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Chieti, Italy, 66100
- GSK Investigational Site
-
Cremona, Italy, 26100
- GSK Investigational Site
-
Perugia, Italy, 06156
- GSK Investigational Site
-
Reggio Emilia, Italy, 42100
- GSK Investigational Site
-
Varese, Italy, 21100
- GSK Investigational Site
-
-
Emilia-Romagna
-
Carpi (MO), Emilia-Romagna, Italy, 41012
- GSK Investigational Site
-
Forlì, Emilia-Romagna, Italy, 47100
- GSK Investigational Site
-
Modena, Emilia-Romagna, Italy, 41100
- GSK Investigational Site
-
Piacenza, Emilia-Romagna, Italy, 29100
- GSK Investigational Site
-
Rimini, Emilia-Romagna, Italy, 47900
- GSK Investigational Site
-
-
Lombardia
-
Treviglio (BG), Lombardia, Italy, 24047
- GSK Investigational Site
-
-
Puglia
-
Brindisi, Puglia, Italy, 72100
- GSK Investigational Site
-
-
Toscana
-
Pisa, Toscana, Italy, 56126
- GSK Investigational Site
-
-
-
-
-
Badalona, Spain, 08916
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Histologically confirmed infiltrating primary breast cancer of 2.0 cm or more in largest clinical diameter
- ER and/or PgR positive cancer (> 10% of positive cancer cell assessed by IHC)
Postmenopausal status, defined by at least one of the following:
≥ 60 years of age < 60 years of age and amenorrheic for ≥ 12 months prior to day 1 < 60 years of age and amenorrheic for < 12 months prior to day, or without a uterus: luteinizing hormone (LH) and follicle stimulating hormone (FSH) values within postmenopausal range Prior bilateral oophorectomy Prior radiation castration with amenorrhea for at least 6 months
- HER2 negative tumors (IHC 0-2+, or FISH negative)
- Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment
- Age over 18 years
- ECOG PS 0-1
- Normal organ and marrow function as defined below:
leukocytes > 3000/mL absolute neutrophil count > 1,500/mL platelets > 100,000/mL total bilirubin within normal institutional limits AST (SGOT)/ALT(SGPT)< 2.5 X institutional upper limit of normal Creatinine within normal institutional limits
- Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan.
- Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib will be determined following review of their use by the Principal Investigator.
A list of medications and substances known or with the potential to interact with CYP450 isoenzymes is provided
- Ability to understand and the willingness to sign a written informed consent document.
- Ability to swallow and retain oral medication.
Exclusion criteria:
- Stage IIIB, IIIC, and inflammatory breast cancer
- Stage IV breast cancer
- Contraindication to the treatment with letrozole
- Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment with EGFR targeting therapies
- Treatment with any other investigational agents, or with all herbal (alternative) medicines
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
- Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- HIV-positive patients receiving combination anti-retroviral therapy
- GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)
- Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors (See section 3.7.4.2 Other concomitant treatments)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Letrozole plus placebo
Letrozole 2.5 mg administered orally fro 6 mos.
plus placebo 1500 mg administered orally throughout the study until definitive surgery
|
2.5 mg administered orally daily
1500 mg administered orally daily
|
Experimental: Letrozole plus lapatininb
Letrozole 2.5 mg administered orally fro 6 mos.
plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
|
2.5 mg administered orally daily
1500 mg administered orally daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee
Time Frame: From Baseline (Day 1) up to 6 months, evaluated every 12 weeks
|
cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST).
CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs).
PR for TLs is defined as a >=30% decrease in the sum of the longest diameter (LD) of TLs, taking as a reference the Baseline sum LD.
For non-TLs, it is defined as the persistence of >=1 non-TL and no new TLs or non-TLs.
|
From Baseline (Day 1) up to 6 months, evaluated every 12 weeks
|
Percentage of Participants With Various Responses in the Breast, Evaluated Using Per Protocol Criteria
Time Frame: From Baseline (Day 1) up to 6 months, evaluated every 12 weeks
|
Complete clinical response=nodule not detectable; all ultrasound abnormalities detected at diagnosis have disappeared.
Partial clinical response=the tumor's longest diameter (LD) is reduced by 50% or more; ultrasound characteristics of the tumor persist.
Minimal response=the tumor's LD is reduced by 25%-49%.
Stable disease=the tumor's LD is decreased by less than 25% and is increased by no more than 25% from the starting value.
Progressive disease=the tumor's LD is increased by more than 25% from the starting value.
Participants who were not evaluable did not have data available.
|
From Baseline (Day 1) up to 6 months, evaluated every 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Pathological Complete Response (pCR) in the Breast and Axillary Nodes, Evaluated Using Miller and Payne Criteria
Time Frame: At the point of definitive surgery (up to 6 months after Baseline)
|
pCR is defined as the complete absence of infiltrating tumor cells (TCs) in the breast and lymph nodes.
Miller and Payne criteria: Grade 1, no change/some alteration to individual malignant cells, but no reduction in overall cellularity; Grade 2, up to a 30% loss in TCs; Grade 3, between an estimated 30% and 90% reduction in TCs; Grade 4, more than a 90% reduction in TCs, only small cluster/dispersed cells remaining; Grade 5, no malignant identifiable cells; carcinoma in the milk ducts may be present.
Grades 1 and 2 = No response; Grades 3 and 4= PR; Grade 5 = CR.
|
At the point of definitive surgery (up to 6 months after Baseline)
|
Number of Participants With Breast Tumors Per Pathological Stage at Surgery
Time Frame: At the point of definitive surgery (up to 6 months after Baseline)
|
Tumors were categorized as follows: T0, no evidence of primary tumor, but carcinoma of the milk ducts, accumulation of abnormal cells in the breast lobules, or Paget disease (cancer condition that appears like a skin disease involving the breast nipple) with no associated tumor mass; T1, tumor was <=2 centimeters (cm) across; T2, tumor was >2 cm but <5 cm across; T3, tumor was >5 cm across; T4, tumor of any size growing into the chest wall or skin, including inflammatory breast cancer.
|
At the point of definitive surgery (up to 6 months after Baseline)
|
Number of Participants With the Indicated Nodal Status at Surgery
Time Frame: At the point of definitive surgery (up to 6 months after Baseline)
|
The nodal status of cancer indicates the involvement of lymph nodes in the participant with cancer.
N0 indicates no involvement of lymph nodes, and N+ indicates involvement of lymph nodes.
|
At the point of definitive surgery (up to 6 months after Baseline)
|
Number of Participants With the Indicated Type of Surgery
Time Frame: At the point of definitive surgery (up to 6 months after Baseline 1)
|
Mastectomy is the medical term for the surgical removal of one or both breasts.
Breast-conserving surgery (BCS) involves removing only the affected part of the breast tissue during surgery, as opposed to removal of the entire breast.
|
At the point of definitive surgery (up to 6 months after Baseline 1)
|
Percentage of Participants With Conversion From Planned Mastectomy at Baseline to BCS at Surgery
Time Frame: At the point of definitive surgery (up to 6 months after Baseline)
|
The percentage of participants who were planned to undergo a mastectomy at baseline but later underwent BCS was measured.
|
At the point of definitive surgery (up to 6 months after Baseline)
|
Number of Participants With the Indicated Adverse Events With a Classification of >=Grade 2
Time Frame: From Baseline (Day 1) up to 6 months (until definitive surgery)
|
Toxicity was measured in grades (severity of the AE) as per National Cancer Institute Common Toxicity Criteria for Adverse Event (NCI CTCAE) version (v) 3.0.
The CTCAE v3.0 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life-threatening/disabling; Grade 5, death related to the AE.
Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, and hypertension is high blood pressure.
|
From Baseline (Day 1) up to 6 months (until definitive surgery)
|
Mean Left Ventricular Ejection Fraction (LVEF)
Time Frame: Baseline (Day 1), after 12 weeks, and after 24 weeks
|
Cardiac safety was evaluated as any signs or symptoms of deterioration in LVEF.
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction.
LVEF was evaluated using NCI CTCAE.
|
Baseline (Day 1), after 12 weeks, and after 24 weeks
|
Time to Treatment Failure From the Start of the Primary Therapy
Time Frame: From Baseline (Day 1) up to study withdrawal (approx. 66 months)
|
Time to treatment failure is calculated as the interval between the date of randomization and the occurrence of local tumor progression (including ipsilateral [on the same side] and controlateral breast tumor progression), distant tumor progression, permanent treatment discontinuation (either for the experimental or conventional treatment arm), or death for any cause.
|
From Baseline (Day 1) up to study withdrawal (approx. 66 months)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protein Kinase Inhibitors
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Lapatinib
Other Study ID Numbers
- EGF107692
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Breast
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Providence Health & ServicesBrooklyn ImmunoTherapeutics, LLCActive, not recruitingBreast Neoplasm | Triple Negative Breast Cancer | Breast Neoplasm, MaleUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
Clinical Trials on letrozole
-
Helsinki University Central HospitalFoundation for Paediatric Research, FinlandCompletedConstitutional Delay of Growth and PubertyFinland
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
Institut du Cancer de Montpellier - Val d'AurelleNovartisCompleted
-
University of Alabama at BirminghamGenentech, Inc.; Breast Cancer Research FoundationCompletedBreast Cancer | Breast Neoplasm | Cancer of the BreastUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedBreast Neoplasms
-
IVI MadridActive, not recruitingLuteinised Follicular CystSpain
-
Fudan UniversityRecruitingEndometrial CancerChina
-
Assiut UniversityRecruitingInfertility, FemaleEgypt
-
Cairo UniversityAhmed Elgazzar HospitalCompleted
-
Genor Biopharma Co., Ltd.Recruiting